Merck's Phase III KEYLYNK-006 Trial of Keytruda Plus Lynparza Fails to Meet Primary Endpoints in First-Line Non-Squamous NSCLC

Mar 22, 2024 07:47 CST Updated 07:48

MSD

Pharmaceutical R&D and Manufacturer

March 21,MSDAnnouncing its PD-1 therapyKeytrudaCombined maintenance PARP inhibitor Lynparza (Olaparib) First-line treatment for certain patients with metastatic non-squamous non-small cell lung cancer (NSCLC) in Phase III KEYLYNK-006 Trial Fails to Meet Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS)。

In the KEYLYNK-006 trial, compared with Keytruda combined with chemotherapy (Pemetrexed+CarboplatinCompared with Keytruda + maintenance chemotherapy (pemetrexed) after platinum-based doublet chemotherapy (carboplatin or cisplatin), Keytruda in combination with chemotherapy followed by Keytruda + maintenance Lynparza did not meet the pre-specified statistical criteria for OS or PFS. The safety of Keytruda and Lynparza in this trial was consistent with the findings observed in previously reported monotherapy studies. A comprehensive evaluation of the study data is ongoing. Merck & Co., Inc. stated that it will collaborate with researchers to share the study results with the scientific community.

In fact, this is not the first Phase III study where the Keytruda + Olaparib combination therapy has failed; last year,On December 7, MSD announced the terminationKeytrudaAndLynparza (Olaparib) Combination Therapy for Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)Phase III KEYLYNK-008 Trial, the reason is under investigationNo improvement in OS was observed (see:MSD Terminates a Phase III Study of K Drug + Olaparib Combination Therapy）。

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprinting, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Exciting Preview

↑Long press to identify QR code / ScanRegistration is now open.↑